ArticleCureus2025
Diagnostic Value of Exercise Stress Testing Combined With Beta-Blocker Therapy (Metoprolol) in Hypertensive Patients With Suspected Coronary Artery Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a prevalent risk factor for coronary artery disease (CAD), and early diagnosis is critical for preventing adverse cardiovascular events. While exercise stress testing (EST) is a common non-invasive tool, its diagnostic performance in hypertensive individuals, especially when combined with beta-blocker therapy, remains under-evaluated. The beta-blocker metoprolol may enhance diagnostic accuracy in this population.
objectiveThis study aimed to evaluate the diagnostic value of EST combined with metoprolol therapy in hypertensive patients with suspected CAD. METHODOLOGY: This prospective, hospital-based controlled diagnostic study was conducted at the Department of Cardiology, Abbas Institute of Medical Science (AIMS), Muzaffarabad, Azad Jammu and Kashmir (AJK), from January 2023 to December 2024. A total of 224 hypertensive patients aged between 30 and 70 years with clinical suspicion of CAD (based on anginal symptoms, ECG changes, or physician judgment) were enrolled. Patients with a known history of CAD, contraindications to exercise or beta-blockers, or current beta-blocker use were excluded. All participants received a single oral dose of 50 mg metoprolol tartrate one hour prior to EST, performed using the Bruce protocol. Adverse effects and hemodynamic responses were monitored. A positive EST was defined by ischemic ECG changes, anginal symptoms, or abnormal blood pressure response. All patients underwent confirmatory testing with either coronary angiography or myocardial perfusion imaging (MPI), depending on clinical indication. Diagnostic metrics, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated using confirmed CAD status as the gold standard. Confidence intervals were calculated to assess the precision of diagnostic estimates. Data were analyzed using IBM SPSS Statistics software, version 25.0 (IBM Corp., Armonk, NY), with categorical variables reported as frequencies and percentages, continuous variables as mean ± SD, and diagnostic accuracy of EST with metoprolol evaluated against confirmed CAD using sensitivity, specificity, PPV, NPV, and chi-square test (p < 0.05).
resultsOut of 224 patients, 138 (61.61%) had a negative EST and 86 (38.39%) had a positive result. CAD was confirmed in 94 patients (41.96%). Of the 86 patients with a positive EST, 68 (79.07%) had confirmed CAD. Among the 138 patients with a negative EST, 26 (18.84%) were found to have CAD. The combination of EST and metoprolol demonstrated a diagnostic sensitivity of 72.34%, specificity of 86.15%, PPV of 79.07%, NPV of 81.16%, and an overall diagnostic accuracy of 80.36%.
conclusionIn hypertensive patients with suspected CAD, combining EST with metoprolol provides a viable and non-invasive diagnostic strategy, offering high specificity and PPV despite moderate sensitivity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.